AdvanCell secures $315M Series D to advance lead-based prostate cancer therapy

AdvanCell announced a $315 million Series D financing round aimed at supporting development of its lead-based prostate cancer agent and expanding U.S. manufacturing capacity for the radioactive treatment.

The funds will be used to advance clinical studies of the candidate, which is positioned as a potential competitor to existing therapies such as Pluvicto. The round is noted as one of the largest raised by a radiopharmaceutical company.

Investors view the capital raise as a vote of confidence in the radiopharma sector, and the additional resources could speed the company’s path toward market approval, potentially expanding options for prostate cancer patients.